Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SI)
USD 2.19
(1.86%)
USD 2.19
(1.86%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 688.48 Million | 677.24 Million | 852.4 Million | 671.42 Million | 495.48 Million | 350.14 Million |
| Net Income | 968.7 Million | 873.25 Million | 786.87 Million | 679.66 Million | 635.35 Million | 567.78 Million |
| Depreciation & Amortization | 130.12 Million | 116.55 Million | 115.53 Million | 110.84 Million | 98.14 Million | 76.14 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 18.97 Million | - | - | - | - | - |
| Change in working capital | -206.51 Million | -120.14 Million | 141.6 Million | 39.03 Million | -62.4 Million | -143.65 Million |
| Other non-cash items | -203.83 Million | -192.42 Million | -191.61 Million | -158.12 Million | -175.61 Million | -150.13 Million |
| Investing Cash Flow | -568.91 Million | -12.27 Million | -311.85 Million | 73.77 Million | -100.79 Million | 381.95 Million |
| Investments in PPE | -140.92 Million | -107.9 Million | -156.94 Million | -189.16 Million | -205.61 Million | -175.8 Million |
| Acquisitions | 0.79 | -47.61 Million | 1.06 | 195.93 Million | 243.96 Million | 1.52 Million |
| Investment purchases | -656 Million | -530 Million | -349.92 Million | -34.47 Billion | -71.55 Billion | -38.66 Billion |
| Sales/Maturities of investments | 227.83 Million | 671.74 Million | 166.3 Million | 34.73 Billion | 71.61 Billion | 39.23 Billion |
| Other Investing Activities | 185.91 Thousand | 1.48 Million | 28.71 Million | -189.16 Million | -205.61 Million | -11.58 Million |
| Financing Cash Flow | -833.76 Million | -236.61 Million | -244.7 Million | -237.26 Million | -370.36 Million | -252.14 Million |
| Debt repayment | -800.96 Million | -24.17 Million | - | - | -352 Million | -382 Million |
| Dividends payments | -877.32 Million | -387.43 Million | -232.05 Million | -232.6 Million | - | - |
| Common Stock Repurchased | -22.66 Million | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -26.34 Million | 174.98 Million | -12.64 Million | -4.65 Million | 154.99 Million | 294.6 Million |
| Accounts receivables | 74 Million | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | -165.33 Million | 58.87 Million | -47.4 Million | 110.95 Million | -292.56 Million | -239.99 Million |
| Other working capital | -41.17 Million | -179.01 Million | 189 Million | -71.92 Million | 230.15 Million | 96.34 Million |
| Cash at beginning of period | 2.71 Billion | 2.28 Billion | 1.98 Billion | 1.47 Billion | 1.45 Billion | 975.11 Million |
| Cash at end of period | 1.99 Billion | 2.71 Billion | 2.28 Billion | 1.98 Billion | 1.47 Billion | 1.45 Billion |
| Capital Expenditure | -140.92 Million | -107.9 Million | -156.94 Million | -189.16 Million | -205.61 Million | -175.8 Million |
| Effect of forex changes on cash | 45.34 Thousand | 5975.36 | 0.22 | 0.17 | 0.38 | 0.95 |
| Net cash flow / Change in cash | -714.14 Million | 428.35 Million | 295.84 Million | 507.93 Million | 24.33 Million | 479.95 Million |
| Free Cash Flow | 547.56 Million | 569.34 Million | 695.45 Million | 482.25 Million | 289.87 Million | 174.33 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | 328.85 Million | - | 968.7 Million | - | - |
| Depreciation & Amortization | - | 31.55 Million | - | 130.12 Million | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 174.78 Thousand | - | - | - | - |
| Change in working capital | - | -151.22 Million | - | -206.51 Million | - | - |
| Other non-cash items | - | 68.23 Million | - | -203.83 Million | - | - |
| Investing Cash Flow | -1.24 Billion | -51.36 Million | 116.44 Million | -568.91 Million | -83.27 Million | 1.54 Million |
| Investments in PPE | -42.46 Million | -23.11 Million | -14.19 Million | -140.92 Million | -57.27 Million | -18.54 Million |
| Acquisitions | - | - | - | 0.79 | - | -0.25 |
| Investment purchases | -1.2 Billion | -70 Million | -40 Million | -656 Million | -26 Million | -50 Million |
| Sales/Maturities of investments | 3.6 Million | 41.69 Million | 170.61 Million | 227.83 Million | - | 70.09 Million |
| Other Investing Activities | - | 53.19 Thousand | - | 185.91 Thousand | -100.44 | - |
| Financing Cash Flow | -751.41 Million | 425.45 Million | 294.43 Million | -833.76 Million | -456.26 Million | -33.07 Million |
| Debt repayment | -221.09 Million | -434.99 Million | -300 Million | -800.96 Million | -600.57 Million | -177.89 Million |
| Dividends payments | -971.98 Million | -8.95 Million | -2.22 Million | -877.32 Million | -6.44 Million | -4.66 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -529.8 Thousand | -580.97 Thousand | -3.34 Million | -26.34 Million | -1.03 Million | 149.47 Million |
| Accounts receivables | - | -151.71 Million | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | 499.01 Thousand | - | -165.33 Million | - | - |
| Other working capital | - | - | - | -41.17 Million | - | - |
| Cash at beginning of period | 3.33 Billion | 2.31 Billion | 1.99 Billion | 2.71 Billion | 1.92 Billion | 2 Billion |
| Cash at end of period | 1.35 Billion | 3.33 Billion | 2.31 Billion | 1.99 Billion | 1.99 Billion | 1.92 Billion |
| Capital Expenditure | -42.46 Million | -23.11 Million | -14.19 Million | -140.92 Million | -57.27 Million | -18.54 Million |
| Effect of forex changes on cash | -44.14 Thousand | -12.27 Thousand | -55.93 Thousand | 45.34 Thousand | 860.9 Thousand | 6357.28 |
| Net cash flow / Change in cash | -1.97 Billion | 1.01 Billion | 321.52 Million | -714.14 Million | 68.62 Million | -72.76 Million |
| Free Cash Flow | -42.46 Million | 254.49 Million | -14.19 Million | 547.56 Million | 550.02 Million | -59.79 Million |
VOYA-PB
6707
DECK
PJAA
ZHSHF
WSTEP